Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR

Key Points

• Hennion & Walsh Asset Management bought 396,726 Larimar Therapeutics shares worth approximately $1.21 million, while institutional investors collectively own 91.92% of the company.
• Director Thomas Edward Hamilton purchased 50,000 shares at $3.34 each, increasing his holdings by 7.52%; insiders own 4% of the stock.
• Larimar reported a quarterly loss of $0.30 per share, beating estimates by $0.08. Analysts maintain a consensus “Buy” rating with a $12.57 price target, well above the stock’s reported $4.37 price.

Hennion & Walsh Asset Management Inc. purchased a new position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 396,726 shares of the company's stock, valued at approximately $1,210,000. Hennion & Walsh Asset Management Inc. owned approximately 0.38% of Larimar Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. AQR Capital Management LLC purchased a new position in shares of Larimar Therapeutics during the 1st quarter valued at approximately $241,000. Acadian Asset Management LLC acquired a new stake in Larimar Therapeutics in the 1st quarter valued at $113,000. Rhumbline Advisers increased its holdings in Larimar Therapeutics by 15.7% in the 1st quarter. Rhumbline Advisers now owns 65,018 shares of the company's stock worth $140,000 after acquiring an additional 8,818 shares in the last quarter. American Century Companies Inc. increased its holdings in Larimar Therapeutics by 7.8% in the 2nd quarter. American Century Companies Inc. now owns 69,285 shares of the company's stock worth $200,000 after acquiring an additional 5,001 shares in the last quarter. Finally, Cerity Partners LLC acquired a new position in Larimar Therapeutics during the second quarter worth $636,000. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Thomas Edward Hamilton purchased 50,000 shares of the business's stock in a transaction that occurred on Monday, July 6th. The stock was purchased at an average price of $3.34 per share, with a total value of $167,000.00. Following the completion of the acquisition, the director owned 714,798 shares in the company, valued at $2,387,425.32. This trade represents a 7.52% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 4.00% of the stock is owned by company insiders.

Larimar Therapeutics Stock Up 1.4%

Larimar Therapeutics stock opened at $4.37 on Thursday. The company has a fifty day simple moving average of $3.70 and a 200-day simple moving average of $4.01. The firm has a market capitalization of $453.96 million, a price-to-earnings ratio of -2.24 and a beta of 0.81. Larimar Therapeutics, Inc. has a 52-week low of $2.71 and a 52-week high of $6.42.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.08. On average, research analysts anticipate that Larimar Therapeutics, Inc. will post -1.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on LRMR. HC Wainwright initiated coverage on shares of Larimar Therapeutics in a report on Thursday, July 2nd. They set a "buy" rating and a $10.00 price objective on the stock. Wall Street Zen upgraded shares of Larimar Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 16th. Citigroup reaffirmed a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, June 30th. Robert W. Baird cut their price objective on Larimar Therapeutics from $7.00 to $5.00 and set an "outperform" rating for the company in a research note on Tuesday, June 30th. Finally, Wedbush reduced their target price on Larimar Therapeutics from $12.00 to $11.00 and set an "outperform" rating for the company in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $12.57.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source